MX2016010877A - Amidas antimitoticas para el tratamiento del cancer y desordenes proliferativos. - Google Patents

Amidas antimitoticas para el tratamiento del cancer y desordenes proliferativos.

Info

Publication number
MX2016010877A
MX2016010877A MX2016010877A MX2016010877A MX2016010877A MX 2016010877 A MX2016010877 A MX 2016010877A MX 2016010877 A MX2016010877 A MX 2016010877A MX 2016010877 A MX2016010877 A MX 2016010877A MX 2016010877 A MX2016010877 A MX 2016010877A
Authority
MX
Mexico
Prior art keywords
antimitotic
cancer
treatment
amides
proliferative disorders
Prior art date
Application number
MX2016010877A
Other languages
English (en)
Inventor
Siddiqui-Jain Adam
Original Assignee
Frost Biologic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Frost Biologic Inc filed Critical Frost Biologic Inc
Publication of MX2016010877A publication Critical patent/MX2016010877A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se describen nuevas heteroaril amidas antimitóticas y sales farmacéuticamente aceptables de la Formula I en donde Ar, R5, R6, R8, R9, R11, X1, y X2 son como se definen en la presente, como compuestos para el tratamiento y la prevención del cáncer y desordenes y enfermedades proliferativas. (Ver Fórmula).
MX2016010877A 2014-02-21 2015-02-20 Amidas antimitoticas para el tratamiento del cancer y desordenes proliferativos. MX2016010877A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461942956P 2014-02-21 2014-02-21
PCT/US2015/016928 WO2015127284A2 (en) 2014-02-21 2015-02-20 Antimitotic amides for the treatment of cancer and proliferative disorders

Publications (1)

Publication Number Publication Date
MX2016010877A true MX2016010877A (es) 2017-05-04

Family

ID=52684675

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016010877A MX2016010877A (es) 2014-02-21 2015-02-20 Amidas antimitoticas para el tratamiento del cancer y desordenes proliferativos.

Country Status (14)

Country Link
US (4) US10016398B2 (es)
EP (1) EP3107909B1 (es)
JP (1) JP6506313B2 (es)
KR (1) KR102420508B1 (es)
CN (2) CN114634483A (es)
AU (1) AU2015218775C1 (es)
BR (1) BR112016019161B1 (es)
CA (1) CA2940237C (es)
ES (1) ES2893374T3 (es)
IL (1) IL247293B (es)
MX (1) MX2016010877A (es)
RU (1) RU2713179C2 (es)
SG (2) SG11201606869TA (es)
WO (1) WO2015127284A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6420622B1 (en) 1997-08-01 2002-07-16 3M Innovative Properties Company Medical article having fluid control film
RU2713179C2 (ru) * 2014-02-21 2020-02-04 Фрост Биолоджик, Инк. Антимитотические амиды для лечения рака и пролиферативных заболеваний
CN106727583A (zh) * 2016-12-12 2017-05-31 范旭升 一种治疗舒张性心衰的药物组合物
WO2019014460A1 (en) * 2017-07-12 2019-01-17 The Brigham And Women's Hospital, Inc. MOLECULES ENHANCING EAAT2
WO2019168874A1 (en) 2018-02-27 2019-09-06 The Research Foundation For The State University Of New York Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001930D0 (en) * 2000-01-27 2000-03-22 Novartis Ag Organic compounds
EP1289984A4 (en) * 2000-06-05 2004-11-24 Dong A Pharm Co Ltd NEW OXAZOLIDE DERIVATIVES AND A METHOD FOR THEIR PRODUCTION
US6995162B2 (en) * 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
GB0209715D0 (en) * 2002-04-27 2002-06-05 Astrazeneca Ab Chemical compounds
RU2007103299A (ru) * 2004-06-30 2008-08-10 Новартис АГ (CH) Способ повышения чувствительности к ингибиторам пептиддеформилазы с помощью ингибиторов откачивающего насоса
US20090156646A1 (en) * 2005-08-11 2009-06-18 Takeda Pharmaceutical Company Limited Pyridylphenol compound and use thereof
DK1984338T3 (da) * 2006-01-31 2013-04-22 Synta Pharmaceuticals Corp Pyridylphenylforbindelser til inflammations- og immunrelaterede anvendelser
WO2008059042A1 (en) 2006-11-17 2008-05-22 Smithkline Beecham Corporation 2-carboxy thiophene derivatives as anti viral agents
JP2010523639A (ja) * 2007-04-12 2010-07-15 エフ．ホフマン−ラ ロシュ アーゲー 医薬化合物
US20110118281A9 (en) * 2008-10-01 2011-05-19 Gary Bohnert Compounds for inflammation and immune-related uses
WO2010100475A1 (en) * 2009-03-02 2010-09-10 Astrazeneca Ab Hydroxamic acid derivatives as gram-negative antibacterial agents
ES2528485T3 (es) * 2009-09-11 2015-02-10 Amgen, Inc N-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oxi)fenil)-4-(4-metil-2-tienil)-1-ftalazinamina para su uso en el tratamiento del cáncer resistente a agentes antimitóticos
JP6112486B2 (ja) 2010-04-27 2017-04-12 カルシメディカ，インク． 細胞内カルシウムを調節する化合物
US20130063385A1 (en) * 2010-05-14 2013-03-14 Sharp Kabushiki Kaisha Portable information terminal and method for controlling same
TWI541243B (zh) * 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
EP2665711A1 (en) * 2011-01-21 2013-11-27 Abbvie Inc. Picolinamide inhibitors of kinases
BR112013020270A2 (pt) * 2011-02-10 2016-07-12 Syngenta Participations Ag derivados de pirazol microbicidas
EP2704701B1 (en) * 2011-05-03 2018-01-03 PRCL Research Inc. Compounds for inflammation and immune-related uses
EP2771009A1 (en) * 2011-10-28 2014-09-03 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
RU2713179C2 (ru) * 2014-02-21 2020-02-04 Фрост Биолоджик, Инк. Антимитотические амиды для лечения рака и пролиферативных заболеваний

Also Published As

Publication number Publication date
RU2016135555A (ru) 2018-03-28
RU2016135555A3 (es) 2018-10-05
RU2713179C2 (ru) 2020-02-04
US20170172984A1 (en) 2017-06-22
WO2015127284A3 (en) 2015-10-15
IL247293A0 (en) 2016-09-29
CA2940237C (en) 2023-03-07
US20200397758A1 (en) 2020-12-24
US11129813B2 (en) 2021-09-28
CA2940237A1 (en) 2015-08-27
AU2015218775C1 (en) 2020-01-16
SG11201606869TA (en) 2016-09-29
IL247293B (en) 2021-01-31
KR20160116009A (ko) 2016-10-06
BR112016019161B1 (pt) 2022-12-20
ES2893374T3 (es) 2022-02-08
WO2015127284A2 (en) 2015-08-27
US20180325871A1 (en) 2018-11-15
JP2017506267A (ja) 2017-03-02
AU2015218775A1 (en) 2016-08-25
CN106068263A (zh) 2016-11-02
US10016398B2 (en) 2018-07-10
EP3107909B1 (en) 2021-07-14
JP6506313B2 (ja) 2019-04-24
KR102420508B1 (ko) 2022-07-13
US20220008395A1 (en) 2022-01-13
BR112016019161A2 (es) 2017-08-15
EP3107909A2 (en) 2016-12-28
US10772872B2 (en) 2020-09-15
SG10202000590SA (en) 2020-03-30
CN114634483A (zh) 2022-06-17
AU2015218775B2 (en) 2019-06-20

Similar Documents

Publication Publication Date Title
HK1247922A1 (zh) 用於治療癌症的吲哚胺2，3-雙加氧酶抑制劑
PH12018502102A1 (en) Pyrrolotriazine compounds as tam inhibitors
MX2018002402A (es) Compuestos de heteroarilo o arilo biciclicos fusionados como moduladores de la quinasa 4 asociada al receptor de la interleucina 1 (irak4).
PH12016501972B1 (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
PH12016502179A1 (en) Inhibitors of lysine specific demethylase-1
TW201613872A (en) IRAK4 inhibiting agents
MA39986A (fr) Dérivés de purine en tant qu'inhibiteurs de cd73 pour le traitement du cancer
NZ726723A (en) Heteroaryl compounds for kinase inhibition
GEP20186933B (en) Substituted dihydroisoquinoline compounds
MX2017006266A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1(irak) y sus usos.
EA201790766A1 (ru) Новые соединения метилпиперидина, подходящие для ингибирования микросомальной простагландин-e2-синтазы 1
MY197698A (en) Oxysterols and methods of use thereof
SA519402288B1 (ar) مركب بيريميدين واستخداماته الصيدلانية
MX2016009663A (es) Derivados de icariina.
PH12017500095A1 (en) Imidazopyridazine compounds
TW201613864A (en) Novel compounds
PH12017500459A1 (en) Azetidinyloxyphenylpyrrolidine compounds
TN2019000210A1 (en) Antitumoral compounds
MX2016010877A (es) Amidas antimitoticas para el tratamiento del cancer y desordenes proliferativos.
NZ730816A (en) Quinoline carboxamides for use in the treatment of multiple myeloma
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
EA033423B1 (ru) Циклопропанбензофуранилпиридопиразиндионы
NZ732704A (en) Quinoline carboxamides for use in the treatment of leukemia
JOP20190163B1 (ar) منشط nrf2
SG10201903630UA (en) Iminosugars useful for the treatment of viral diseases